Update: Moving closer to Kiacta Phase III data
Bellus’s lead candidate, Kiacta, continues to move forward in the pivotal Phase III trial for AA amyloidosis. Recruitment was completed in January 2015 with 261 patients and 80 of the required 120 events to complete study have already been triggered. Data is expected in 2016 and we estimate the probability of success at 60%, given positive efficacy trends in a previous Phase II/III study and design elements that could raise the likelihood of statistical separation vs placebo. The potential for premium pricing and extended market exclusivity drive our rNPV of C$136m.Bellus Health is engaged in the research, development and commercialization of products for health solutions. Co.'s principal business activity has been the development of its core technology platform, amyloid inhibitors, which focuses on chemical compounds that could have the potential to inhibit the formation, deposition and toxicity of amyloid fibrils which are implicated or believed to be the underlying causes of certain diseases. The diseases targeted by Co. include Amyloid A (AA) amyloidosis as well as Alzheimer's disease. KIACTA™ is being developed to treat AA amyloidosis meanwhile NRM8499, prodrug of tramiprosate is being developed to treat Alzheimer's disease.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.